|
Leader
|
|
|
00000nz a2200037n 45 0 |
|
001
|
|
|
WKP|Q87824081
(VIAF cluster)
(Authority/Source Record)
|
|
003
|
|
|
WKP |
|
005
|
|
|
20241221010858.0 |
|
008
|
|
|
241221nneanz||abbn n and d |
|
035
|
|
|
‡a
(WKP)Q87824081
|
|
024
|
|
|
‡a
0000-0003-4961-2027
‡2
orcid
|
|
035
|
|
|
‡a
(OCoLC)Q87824081
|
|
100
|
0 |
|
‡a
Maureen J Lage
‡c
researcher
‡9
en
|
|
400
|
0 |
|
‡a
Maureen J Lage
‡c
wetenschapper
‡9
nl
|
|
670
|
|
|
‡a
Author's Adherence to Basal Insulin Therapy Among People with Type 2 Diabetes: A Retrospective Cohort Study of Costs and Patient Outcomes.
|
|
670
|
|
|
‡a
Author's Chronic Medication Burden and Complexity for US Patients with Type 2 Diabetes Treated with Glucose-Lowering Agents
|
|
670
|
|
|
‡a
Author's Generalizability of glucagon‐like peptide‐1 receptor agonist cardiovascular outcome trials to the overall type 2 diabetes population in the United States
|
|
670
|
|
|
‡a
Author's Glucagon-Like Peptide-1 Receptor Agonist Use and Renal Impairment: A Retrospective Analysis of an Electronic Health Records Database in the U.S. Population.
|
|
909
|
|
|
‡a
(orcid) 0000000349612027
‡9
1
|
|
919
|
|
|
‡a
glucagonlikepeptide1receptoragonistuseandrenalimpairmentaretrospectiveanalysisofanelectronichealthrecordsdatabaseintheuspopulation
‡A
Glucagon-Like Peptide-1 Receptor Agonist Use and Renal Impairment: A Retrospective Analysis of an Electronic Health Records Database in the U.S. Population.
‡9
1
|
|
919
|
|
|
‡a
adherencetobasalinsulintherapyamongpeoplewithtype2diabetesaretrospectivecohortstudyofcostsandpatientoutcomes
‡A
Adherence to Basal Insulin Therapy Among People with Type 2 Diabetes: A Retrospective Cohort Study of Costs and Patient Outcomes.
‡9
1
|
|
919
|
|
|
‡a
chronicmedicationburdenandcomplexityforuspatientswithtype2diabetestreatedwithglucoseloweringagents
‡A
Chronic Medication Burden and Complexity for US Patients with Type 2 Diabetes Treated with Glucose-Lowering Agents
‡9
1
|
|
919
|
|
|
‡a
generalizabilityofglucagonlikepeptide1receptoragonistcardiovascularoutcometrialstotheoveralltype2diabetespopulationintheunitedstates
‡A
Generalizability of glucagon‐like peptide‐1 receptor agonist cardiovascular outcome trials to the overall type 2 diabetes population in the United States
‡9
1
|
|
996
|
|
|
‡2
ISNI|0000000431853647
|
|
996
|
|
|
‡2
ISNI|0000000122403837
|
|
996
|
|
|
‡2
SUDOC|076367320
|
|
996
|
|
|
‡2
LC|nb2018009175
|
|
996
|
|
|
‡2
PTBNP|1193202
|
|
996
|
|
|
‡2
ISNI|0000000358491597
|
|
996
|
|
|
‡2
DNB|170994163
|
|
997
|
|
|
‡a
0 0 lived 0 0
‡9
1
|
